Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000950170-25-047758
Filing Date
2025-03-31
Accepted
2025-03-31 16:18:18
Documents
81
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-K tcrt-20241231.htm   iXBRL 10-K 2391808
2 EX-10.59 tcrt-ex10_59.htm EX-10.59 52158
3 EX-10.60 tcrt-ex10_60.htm EX-10.60 94907
4 EX-10.61 tcrt-ex10_61.htm EX-10.61 55146
5 EX-10.62 tcrt-ex10_62.htm EX-10.62 85619
6 EX-19.1 tcrt-ex19_1.htm EX-19.1 178107
7 EX-23.1 tcrt-ex23_1.htm EX-23.1 4775
8 EX-23.2 tcrt-ex23_2.htm EX-23.2 4687
9 EX-31.1 tcrt-ex31_1.htm EX-31.1 15030
10 EX-32.1 tcrt-ex32_1.htm EX-32.1 8233
11 EX-97.1 tcrt-ex97_1.htm EX-97.1 40710
  Complete submission text file 0000950170-25-047758.txt   9776575

Data Files

Seq Description Document Type Size
12 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT tcrt-20241231.xsd EX-101.SCH 1469873
83 EXTRACTED XBRL INSTANCE DOCUMENT tcrt-20241231_htm.xml XML 1368835
Mailing Address 2617 BISSONNET ST SUITE 233 HOUSTON TX 77005
Business Address 2617 BISSONNET ST SUITE 233 HOUSTON TX 77005 (346) 355-4099
Alaunos Therapeutics, Inc. (Filer) CIK: 0001107421 (see all company filings)

EIN.: 841475642 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-33038 | Film No.: 25793519
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)